Constellation Pharmaceuticals (CNST) Sees Strong Trading Volume

Share on StockTwits

Shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) saw unusually-high trading volume on Friday . Approximately 1,273,709 shares were traded during mid-day trading, an increase of 1,387% from the previous session’s volume of 85,647 shares.The stock last traded at $10.00 and had previously closed at $9.89.

CNST has been the subject of several research analyst reports. HC Wainwright initiated coverage on Constellation Pharmaceuticals in a report on Thursday, December 20th. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research raised Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Wednesday, January 9th. Robert W. Baird initiated coverage on Constellation Pharmaceuticals in a report on Monday, January 28th. They issued an “outperform” rating and a $17.00 price objective for the company. Finally, ValuEngine lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Constellation Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $17.25.

Constellation Pharmaceuticals (NASDAQ:CNST) last posted its earnings results on Thursday, March 14th. The company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.03). Sell-side analysts expect that Constellation Pharmaceuticals Inc will post -4.14 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Svennilson Peter bought a new position in shares of Constellation Pharmaceuticals during the fourth quarter valued at approximately $18,759,000. FMR LLC bought a new position in shares of Constellation Pharmaceuticals during the third quarter valued at approximately $10,281,000. Casdin Capital LLC grew its holdings in shares of Constellation Pharmaceuticals by 18.4% during the fourth quarter. Casdin Capital LLC now owns 1,556,998 shares of the company’s stock valued at $6,244,000 after purchasing an additional 242,255 shares during the last quarter. VHCP Management II LLC bought a new position in shares of Constellation Pharmaceuticals during the third quarter valued at approximately $4,891,000. Finally, EcoR1 Capital LLC bought a new position in shares of Constellation Pharmaceuticals during the third quarter valued at approximately $1,884,000. 60.05% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Constellation Pharmaceuticals (CNST) Sees Strong Trading Volume” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4224584/constellation-pharmaceuticals-cnst-sees-strong-trading-volume.html.

Constellation Pharmaceuticals Company Profile (NASDAQ:CNST)

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Featured Article: Bull Market

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Arco Platform Ltd  Given Consensus Rating of “Strong Buy” by Brokerages
Arco Platform Ltd Given Consensus Rating of “Strong Buy” by Brokerages
BMO Capital Markets Upgrades Polaris Industries  to Outperform
BMO Capital Markets Upgrades Polaris Industries to Outperform
Deutsche Boerse  Hits New 52-Week High at $124.50
Deutsche Boerse Hits New 52-Week High at $124.50
MoSys Inc.  Short Interest Update
MoSys Inc. Short Interest Update
Critical Review: AltiGen Communications  vs. Clearone
Critical Review: AltiGen Communications vs. Clearone
Bovis Homes Group  Lowered to “Sell” at Shore Capital
Bovis Homes Group Lowered to “Sell” at Shore Capital


© 2006-2019 Ticker Report